Dahiroc, Rachel L.

HRN: 04-03-01  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
07/16/2025
CO-AMOXICLAV 625MG (TAB)
07/16/2025
07/22/2025
ORAL
625mg
BID
Complicated UTI CKD
Remove - Pending Acceptance
07/16/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
07/16/2025
07/22/2025
IV
2.25gm
Q6
Complicated UTI
Remove - Pending Acceptance
07/22/2025
CEFTAZIDIME 1GM (VIAL)
07/22/2025
07/29/2025
IV
1gm
Q8
Complicated Uti
Remove - Pending Acceptance

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: